|
Friday 6th November 2020 |
Text too small? |
Chair’s Address at Annual Shareholders Meeting
Despite the operational restrictions and financial impact of COVID-19, we achieved our goal of modest EBITDA growth.
For the year ended 30 June, Chorus delivered EBITDA of $648m, delivering net profit of $52m. Operating revenue was down slightly, from $970m in the prior year to $959m. This reduction was more than offset by a reduction in operating expenses from $334m to $311m. We continue to place huge emphasis on cost management and efficiency, particularly as our major build programme starts to taper down. It is not easy, and invariably impacts people on a personal basis as numbers fall.
Credit is due to JB and his team for their relentless focus on this. This enabled payment of fully imputed dividends of 24cps over the course of the financial year. The board anticipates this increasing to 25cps in the current financial year, subject to no material worsening of the operating or regulatory environment.
See the links below for more details:
Source: Chorus Limited
No comments yet
HGH - Heartland 2026 Annual General Meeting
WHS provides FY27 first quarter trading update
AIA - successfully completes new A$300 million AMTN issue
November 13th Morning Report
SPK - Response to open letter regarding FY26 financial statements
HGH - Update on proposed TSB transaction target completion date
MFT - Mainfreight Half Year Financial Results 30 September 2026
MCY - Executive leadership team changes
November 12th Morning Report
GTK - FY26 Investor Briefing Details